Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non–Small-Cell Lung Cancer

Lignende værker

• Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
  af: Aggarwal, Charu, et al.
  Udgivet: (2018)
• KRAS and TP53 Mutations in Colorectal Carcinoma
  af: Al-Kuraya, Khawla S.
  Udgivet: (2009)
• Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
  af: Schabath, Matthew B., et al.
  Udgivet: (2015)
• Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma
  af: Hill, Margaret A., et al.
  Udgivet: (2018)
• Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
  af: Yao Liang, et al.
  Udgivet: (2024-01-01)